Survivorship - lebenslange Begleitung von Krebspatienten

Survivorship - lebenslange Begleitung von Krebspatiente

Finanzielle und soziale Folgen der Krebserkrankung für junge Menschen

Aktuell leben in der Bundesrepublik Deutschland über 1,5 Millionen Menschen seit fünf Jahren mit einer Krebsdiagnose. Dabei leiden gerade junge Erwachsene unter den finanziellen und sozialen Langzeitfolgen einer Krebserkrankung. Bislang gibt es in Deutschland kaum umfassende Darstellungen zur Erwerbstätigkeit nach Krebs sowie zu den Einkommensverlusten, den finanziellen Belastungen und zum Ausmaß von Transferleistungen im Rahmen der sozialen Sicherung. Zudem fehlen gebündelte, niedrigschwellige Beratungsangebote für Betroffene zu sozialrechtlichen Fragen. Im 16. Band der Gesundheitspolitischen Schriftenreihe der DGHO widmet sich die Fachgesellschaft in Zusammenarbeit mit der Deutschen Stiftung für junge Erwachsene mit Krebs dem drängenden Thema der sozialen und finanziellen Langzeitfolgen von Krebserkrankungen bei jungen Erwachsenen. Darüber hinaus stellt der Band Handlungsempfehlungen vor und bietet einen sozialrechtlichen Ratgeber mit praktischen Informationen und Hilfen insbesondere für junge Menschen mit Krebs

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

Emerging numbers of SARS-CoV-2 infections are currently combated with a third vaccination. Considering the different vaccination regimens used for the first two vaccine doses, we addressed whether the previous vaccination influences the immune response to the booster. Participants for this prospective study were recruited from among healthcare workers. N = 20 participants were previously vaccinated with two doses of BNT162b2, and n = 53 received a priming dose of ChAdOx1-nCoV-19 followed by a BNT162b2 dose. Participants were vaccinated with a third dose of BNT162b2 in December 2021. Antibody concentrations were determined after vaccination, and in a subset of n = 19 participants, T cell responses were evaluated. Anti-S concentrations and IFNγ production increased during the first 21 days. The choice of the first and second vaccineshad no influence on the final outcome of the booster vaccination. Before booster vaccination, antibody concentrations were lower for older participants but increased more strongly over time

Rehabilitation care planning on a digital communication platform for patients with a work disability: protocol for the RehaPro-SERVE feasibility study

Background!#!Long-term disability to work is a risk factor for a permanent reduction in income. Rehabilitation care can support people to return to work. In Germany, rehabilitation care to return to work is mostly provided in specialised clinics. The aim of the Rehapro-SERVE study is to reduce work disability days by facilitating rehabilitation care planning using a digital communication platform. To investigate the feasibility, we will test the implementation of the digital platform and evaluate the study procedures. The Rehapro-SERVE study is funded by the German Federal Ministry of Labour and Social Affairs (BMAS) (grant number: 661R0053K1).!##!Method!#!The feasibility study includes a two-armed unblinded block randomised controlled study (RCT) without follow-up assessments as well as an interview study. Participants for the RCT (n = 16) are primary care patients with a minimum of 4 weeks of absence from work due to musculoskeletal, oncological or psychological conditions and at high risk of early retirement. Eligibility criteria are age 40 to 60 years; minimum of 4 weeks continuous sick leave before recruitment due to musculoskeletal, mental health or oncological conditions; and being at high risk of early retirement. Patients will be recruited from 8 primary care practices in urban and rural areas in Hesse, Germany. Following baseline assessments, patients will be randomised to either digitalised care planning (treatment) or a control group. The digitalised care planning platform will include the patients' primary care physicians, jobcentres and public health physicians to decide on a tailored return-to-work programme. The collaboration will be supported by a case administrator and, if considered beneficial, a social worker for the patient. An interview study will evaluate the acceptability of the study procedures and the intervention.!##!Discussion!#!The use of a digital communication platform enables stakeholders to exchange information and discuss rehabilitation care planning in a timely fashion. The results of the feasibility study will lead to the adaptation of study procedures for the main study. The results will support the design and conduct of similar studies including digital applications in primary care or across different healthcare settings.!##!Trial registration!#!DRKS - German Clinical Trials Register, DRKS00024207 . Registered on 22 March 2021